Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation

Abstract

The combination therapy of oral etoposide and estramustine phosphate (EMP) showed promising results for the treatment of hormone-refractory prostate cancer. Binding of EMP to microtubule-associated proteins, tubulin and proteins of the nuclear matrix are currently considered to be the most likely mechanisms underlying the cytotoxicity in androgen-independent prostatic carcinoma. Combination of EMP with etoposide has produced antitumour responses in 30±60% of patients with metastatic hormonerefractory prostate carcinoma. In vitro, EMP and etoposide (VP-16) appeared to act synergistically to inhibit the growth of the metastatic human prostate adenocarcinoma cell line PC3. Transforming growth factor b(TGF-b) is growth inhibitory to many malignant cells, including prostate cancer cells. We have previously shown that TGF-b plays a signi®cant role in PC3 cell growth inhibition. This study aimed to de®ne the possible association of activity of antineoplastic agents with TGF-b protein in hormone-refractory prostate cancer cell lines.

DOI: 10.1038/sj.pcan.4500358

Cite this paper

@article{Trkeri1999AugmentedCO, title={Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation}, author={L N T{\"{u}rkeri and Omar Ayaz and Mustafa {\"{O}zy{\"{u}rek and Atif M Akdas}, journal={Prostate Cancer and Prostatic Diseases}, year={1999}, volume={2}, pages={S33-S33} }